Therapy and prophylaxis of Ebola virus infections

Heinz Feldmann, Steven M. Jones, Hans Joachim Schnittler, Thomas Geisbert

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The first cases of Ebola hemorrhagic fever were reported from Sudan and Zaire (now Democratic Republic of the Congo) in 1976, but the virus has only received significant attention since 1995. Until recently, the development of therapeutics or vaccines was not considered a priority, The knowledge gained during the past decade on the biology and pathogenesis of Ebola virus has led to the development of therapeutic strategies that are currently being investigated. Considering the aggressive nature of Ebola infections, in particular the rapid and overwhelming viral burdens, early diagnosis will play a significant role in determining the success of any intervention strategy. Advanced understanding of the immune response has produced several vaccine candidates of which a few can be considered for further evaluation. This review will summarize and discuss the current therapeutic and prophylactic strategies for Ebola hemorrhagic fever.

Original languageEnglish (US)
Pages (from-to)823-830
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume6
Issue number8
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Ebola Hemorrhagic Fever
Democratic Republic of the Congo
Vaccines
Ebolavirus
Sudan
Viral Load
Early Diagnosis
Therapeutics
Viruses

Keywords

  • Ebola virus
  • Filoviridae
  • Pathogenesis
  • Prophylaxis
  • Replication
  • Therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Feldmann, H., Jones, S. M., Schnittler, H. J., & Geisbert, T. (2005). Therapy and prophylaxis of Ebola virus infections. Current Opinion in Investigational Drugs, 6(8), 823-830.

Therapy and prophylaxis of Ebola virus infections. / Feldmann, Heinz; Jones, Steven M.; Schnittler, Hans Joachim; Geisbert, Thomas.

In: Current Opinion in Investigational Drugs, Vol. 6, No. 8, 08.2005, p. 823-830.

Research output: Contribution to journalArticle

Feldmann, H, Jones, SM, Schnittler, HJ & Geisbert, T 2005, 'Therapy and prophylaxis of Ebola virus infections', Current Opinion in Investigational Drugs, vol. 6, no. 8, pp. 823-830.
Feldmann, Heinz ; Jones, Steven M. ; Schnittler, Hans Joachim ; Geisbert, Thomas. / Therapy and prophylaxis of Ebola virus infections. In: Current Opinion in Investigational Drugs. 2005 ; Vol. 6, No. 8. pp. 823-830.
@article{906c3c0505644e3198a43deb8deced14,
title = "Therapy and prophylaxis of Ebola virus infections",
abstract = "The first cases of Ebola hemorrhagic fever were reported from Sudan and Zaire (now Democratic Republic of the Congo) in 1976, but the virus has only received significant attention since 1995. Until recently, the development of therapeutics or vaccines was not considered a priority, The knowledge gained during the past decade on the biology and pathogenesis of Ebola virus has led to the development of therapeutic strategies that are currently being investigated. Considering the aggressive nature of Ebola infections, in particular the rapid and overwhelming viral burdens, early diagnosis will play a significant role in determining the success of any intervention strategy. Advanced understanding of the immune response has produced several vaccine candidates of which a few can be considered for further evaluation. This review will summarize and discuss the current therapeutic and prophylactic strategies for Ebola hemorrhagic fever.",
keywords = "Ebola virus, Filoviridae, Pathogenesis, Prophylaxis, Replication, Therapy",
author = "Heinz Feldmann and Jones, {Steven M.} and Schnittler, {Hans Joachim} and Thomas Geisbert",
year = "2005",
month = "8",
language = "English (US)",
volume = "6",
pages = "823--830",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Therapy and prophylaxis of Ebola virus infections

AU - Feldmann, Heinz

AU - Jones, Steven M.

AU - Schnittler, Hans Joachim

AU - Geisbert, Thomas

PY - 2005/8

Y1 - 2005/8

N2 - The first cases of Ebola hemorrhagic fever were reported from Sudan and Zaire (now Democratic Republic of the Congo) in 1976, but the virus has only received significant attention since 1995. Until recently, the development of therapeutics or vaccines was not considered a priority, The knowledge gained during the past decade on the biology and pathogenesis of Ebola virus has led to the development of therapeutic strategies that are currently being investigated. Considering the aggressive nature of Ebola infections, in particular the rapid and overwhelming viral burdens, early diagnosis will play a significant role in determining the success of any intervention strategy. Advanced understanding of the immune response has produced several vaccine candidates of which a few can be considered for further evaluation. This review will summarize and discuss the current therapeutic and prophylactic strategies for Ebola hemorrhagic fever.

AB - The first cases of Ebola hemorrhagic fever were reported from Sudan and Zaire (now Democratic Republic of the Congo) in 1976, but the virus has only received significant attention since 1995. Until recently, the development of therapeutics or vaccines was not considered a priority, The knowledge gained during the past decade on the biology and pathogenesis of Ebola virus has led to the development of therapeutic strategies that are currently being investigated. Considering the aggressive nature of Ebola infections, in particular the rapid and overwhelming viral burdens, early diagnosis will play a significant role in determining the success of any intervention strategy. Advanced understanding of the immune response has produced several vaccine candidates of which a few can be considered for further evaluation. This review will summarize and discuss the current therapeutic and prophylactic strategies for Ebola hemorrhagic fever.

KW - Ebola virus

KW - Filoviridae

KW - Pathogenesis

KW - Prophylaxis

KW - Replication

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=23344447290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344447290&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 823

EP - 830

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 8

ER -